Bleeding disorders are a group of conditions in which there is a problem with the body's blood clotting process. These disorders can lead to heavy and prolonged bleeding after an injury. Bleeding can also begin on its own.
Normal blood clotting involves as many as 20 different plasma proteins, which are known as blood clotting or coagulation factors. These factors act together with other chemicals to form a substance called fibrin that stops bleeding.
Problems can occur when certain coagulation factors are low or missing. Bleeding problems can range from mild to severe.
Some bleeding disorders are present at birth and are passed through families (inherited). Others develop from:
Illnesses such as vitamin K deficiency or severe liver disease
Treatments such as the use of drugs to stop blood clots (anticoagulants) or the long-term use of antibiotics
Bleeding disorders can also result from having poorly working or too few of the blood cells that promote blood clotting (platelets). These disorders can also be either inherited or picked up (acquired). The side effects of certain drugs often lead to the acquired forms.
Symptoms
Abnormal menstrual bleeding
Bleeding into joints
Excessive bruising
Heavy bleeding
Nosebleeds
Which problems occur depends on the specific bleeding disorder.
Treatment depends on the type of disorder. It may include:
Factor replacement
Fresh frozen plasma transfusion
Platelet transfusion
Other therapies
Outlook (Prognosis)
The outcome also depends on the disorder. Most primary bleeding disorders can be managed. Those due to diseases, such as DIC, depend on how well the disease is treated.
Possible Complications
Bleeding in the brain
Severe bleeding (usually from the gastrointestinal tract or injuries)
Other complications can occur, depending on the disorder.
When to Contact a Medical Professional
Call your health care provider if you notice any unusual or severe bleeding.
Review Date:
3/2/2009
Reviewed By:
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.